Ig Vena

Human Normal Immunoglobulin, the active ingredient in Ig Vena, is an immunoglobulin (human) presented as an intravenous solution for intravenous use. It replaces deficient IgG antibodies in patients with primary or secondary immunodeficiency and modulates immune responses in conditions such as ITP, Kawasaki disease, CIDP and Guillain‑Barré syndrome.

GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products.

Ig Vena, a human immunoglobulin therapy, is used to replace missing antibodies and modulate immune activity in several immunologic and inflammatory disorders.

Primary immunodeficiency diseases: provides IgG replacement to reduce infection frequency and severity. Secondary immunodeficiency (e.g., post‑bone marrow transplantation): restores antibody levels to protect against opportunistic infections. Idiopathic thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. Kawasaki disease: reduces inflammation and coronary artery complications through immune modulation. Chronic inflammatory demyelinating polyneuropathy (CIDP): improves nerve function by dampening autoimmune attack. Guillain‑Barré syndrome: accelerates recovery by providing passive immunity and reducing autoimmune nerve damage.

Ig Vena may be associated with a range of adverse reactions, varying from mild infusion‑related events to rare but serious complications.

Common Side Effects: - Headache - Fever or chills - Nausea or fatigue

Serious or Rare Side Effects: - Anaphylaxis - Thromboembolic events - Acute renal failure

When using Ig Vena, clinicians should observe several safety measures to minimize risks and ensure optimal therapeutic outcomes.

Screen for IgA deficiency: patients with anti‑IgA antibodies may develop severe anaphylactic reactions. Monitor renal function: high protein load can precipitate acute kidney injury, especially in dehydrated patients. Assess thrombotic risk: ensure adequate hydration and consider slower infusion rates in patients with hypercoagulable states. Evaluate pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena can influence the activity of other medicines or be affected by concomitant therapies; awareness of key interactions helps guide safe co‑administration.

Major Interactions (Avoid): - Live vaccines: concurrent administration may reduce vaccine efficacy and increase infection risk. - High‑dose aspirin or anticoagulants: may increase bleeding tendency during infusion.

Moderate Interactions (Monitor Closely): - Intravenous antibiotics (e.g., β‑lactams): Ig can bind and lower antibiotic levels; monitor therapeutic response. - Inactivated vaccines: immune response may be attenuated; assess antibody titers. - Diuretics or nephrotoxic drugs: combined renal stress may heighten risk of kidney injury.